- Home
- AMSF vs IMNM Comparison
AMSF vs IMNM Comparison
Compare AMSF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- IMNM
- Stock Information
- Founded
- AMSF 1985
- IMNM 2006
- Country
- AMSF United States
- IMNM United States
- Employees
- AMSF N/A
- IMNM N/A
- Industry
- AMSF Accident &Health Insurance
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- AMSF Finance
- IMNM Health Care
- Exchange
- AMSF Nasdaq
- IMNM Nasdaq
- Market Cap
- AMSF 869.6M
- IMNM 748.3M
- IPO Year
- AMSF 2005
- IMNM 2020
- Fundamental
- Price
- AMSF $44.16
- IMNM $8.77
- Analyst Decision
- AMSF Buy
- IMNM Strong Buy
- Analyst Count
- AMSF 2
- IMNM 5
- Target Price
- AMSF $59.50
- IMNM $26.40
- AVG Volume (30 Days)
- AMSF 143.6K
- IMNM 1.1M
- Earning Date
- AMSF 07-24-2025
- IMNM 08-11-2025
- Dividend Yield
- AMSF 10.56%
- IMNM N/A
- EPS Growth
- AMSF N/A
- IMNM N/A
- EPS
- AMSF 2.48
- IMNM N/A
- Revenue
- AMSF $301,216,000.00
- IMNM $10,938,000.00
- Revenue This Year
- AMSF $1.69
- IMNM N/A
- Revenue Next Year
- AMSF $6.54
- IMNM $310.65
- P/E Ratio
- AMSF $17.81
- IMNM N/A
- Revenue Growth
- AMSF N/A
- IMNM N/A
- 52 Week Low
- AMSF $42.48
- IMNM $5.15
- 52 Week High
- AMSF $60.24
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- AMSF 47.66
- IMNM 49.38
- Support Level
- AMSF $42.80
- IMNM $8.60
- Resistance Level
- AMSF $44.19
- IMNM $9.27
- Average True Range (ATR)
- AMSF 0.91
- IMNM 0.46
- MACD
- AMSF 0.14
- IMNM -0.03
- Stochastic Oscillator
- AMSF 81.55
- IMNM 44.57
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.